INTRODUCTION
============

*Klebsiella pneumoniae* (*K. pneumoniae*) is a member of the Enterobacteriaceae family, commonly found in the normal microbiota of human skin, and is also an important opportunistic pathogen that is known to cause pneumonia, urinary tract infection (UTI), cholecystitis, upper respiratory tract infection, and wound infection, among others. However, the emergence of multi-drug resistant (MDR) *K. pneumoniae* strains has posed a serious challenge in treating patients, especially in hospitals.[@B1]

Tigecycline is a minocycline derivative, which was among the first identified drugs from the class of glycylcyclines. It is a relatively new drug used for treating complicated skin and soft tissue infections (cSSTI), complicated intra-abdominal infection (cIAI), and community-acquired pneumonia in the Republic of Korea. It is also highly effective against many MDR strains of Enterobacteriaceae, including bacteria with the NDM gene.[@B2] However, since its commercial release, there have been an increasing number of reports of resistance to tigecycline.[@B3][@B4] Furthermore, there is a serious concern about the spread of tigecycline resistant bacteria. The known mechanisms of tigecycline resistance in Enterobacteriaceae to date are the *tetA* gene that encodes an efflux pump;[@B5][@B6] a mutation in the S10 complex of the ribosome;[@B7] and mutations in the *ramR* gene, which results in the overexpression of the AcrAB multi-drug pump.[@B8]

In this study, we collected 342 *K. pneumoniae* isolates from a network of tertiary hospitals that encompass all major provinces, except the island province of Jeju, in the Republic of Korea in 2012. Firstly, we screened for isolates that were nonsusceptible to tigecycline using the disk diffusion method. Next, we attempted to identify the antibiotic resistance mechanism and determine whether this attribute could spread to several other specific clonal types of *K. pneumoniae*.

MATERIALS AND METHODS
=====================

Selection of isolates
---------------------

Twenty-three tertiary hospitals in the Republic of Korea participated in this project, contributing seven to 15 unique clinical isolates from a total of 342 identified as *K. pneumoniae*. The isolates were screened for tigecycline nonsusceptibility using the disk diffusion method, including all isolates with the radius of the zone of 18 millimeters or less.[@B9]

Susceptibility testing
----------------------

Minimum inhibitory concentrations (MIC) of tigecycline and other antibiotics were evaluated for the clinical isolates by the broth dilution method (Sensititre GN2F, Thermo Scientific, Cleveland, OH, USA), and results were interpreted using CLSI 2012 breakpoints.

Determination of the resistance mechanism
-----------------------------------------

The presence of tet genes, such as *tetA*, *B*, *C*, *D*, and *E*, among the isolates was tested using PCR. In addition, we determined the sequences of *ramR* and *rpsJ* (ribosomal S10 protein), as described previously,[@B7] for each of the clinical isolates and manually checked them for single nucleotide polymorphisms, insertions, and deletions that may have contributed to resistance to tigecycline. Furthermore, we used some of the most commonly known primers for the genes *bla*~SHV~, *bla*~TEM~, and *bla*~CTX-M~ to identify markers for cephalosporin and carbapenem resistance among the samples.[@B10]

Multilocus sequence typing
--------------------------

Multilocus sequence typing (MLST) was performed according to the published protocol (<http://www.pasteur.fr/recherche/genopole/PF8/mlst/Kpneumoniae.html>). The clonal types were determined by sequencing the amplified products and submitting them to the MLST website mentioned above. Simultaneously, we performed the eBURST analysis on the webserver <http://eburst.mlst.net/> to identify the clonal complex.

Real-time PCR amplification
---------------------------

After verifying the isolates with mutated *ramR* genes, we performed real-time quantitative PCR (qPCR) amplification to estimate the level of *ramA* expression. The primers were designed as previously described,[@B7] and the SYBR green qPCR kit was used for quantification of expressed *ramA*. The isolates were normalized to isolate ID 23, which was shown not to have a mutation in the *ramR* gene by sequencing.

RESULTS
=======

Tigecycline susceptibility of *K. pneumoniae* isolates
------------------------------------------------------

The disk diffusion method was used to screen the isolates for nonsusceptibility, zones with a radius larger than 18 millimeters. Most of the *K. pneumoniae* isolates were susceptible to tigecycline. However, 16% (56 out of 342) of the isolates demonstrated nonsusceptibility to tigecycline. Possibly because the isolates were selected using the disk diffusion method first, fifty-three isolates had an MIC of greater than 2, two isolates had an MIC of 0.5, and one isolate had an MIC of 2.

The resistance mechanism for tigecycline
----------------------------------------

Nineteen nonsusceptible isolates for tigecycline were positive using PCR amplification for the *tetA* gene, while *tetB*, *C*, *D*, or *E* genes could not be detected. Upon sequencing and analysis of the *ramR* PCR amplification product, 27 mutations in the *ramR* gene were discovered; 12 of them co-existed with the *tetA* and six were exclusively associated with *tetA*. As shown in [Table 1](#T1){ref-type="table"}, eight of the 27 mutations encoded a stop codon, two of which were identical. Of the remaining 19, two mutations of the ST15 resulted in the missense mutation that resulted in a valine instead of alanine; two unrelated clonal types separately resulted in an isoleucine to threonine mutation in the same location. Two isolates of ST11 separately had ISKpn-18 inserts in different locations, as opposed to a previous report.[@B7] The other mutations included deletion of a larger fragment, sequence insertion derived from another plasmid, insertion of a cytosine resulting in frameshift mutations such as; tyrosine to histidine, isoleucine to leucine, threonine to isoleucine, aspartic acid to histidine, lysine to glutamine, and a two-point mutation that resulted in a glycine to glutamic acid and aspartic acid to histidine separately.

Sequencing of the *rpsJ* PCR products yielded nine mutations with missense and single amino acid frameshift mutations. Out of the nine mutants, two co-existed with *ramR* mutations and four with the *tetA* gene. Isolates ST36 and 581 separately carried mutations in all three genes, namely *ramR*, *rpsJ*, and *tetA*.

Cross-resistance profiles of the tigecycline nonsusceptible isolates
--------------------------------------------------------------------

Among the group of 56 nonsusceptible isolates for tigecycline, 37 and 36 were nonsusceptible to ceftazidime and ceftriaxone, respectively ([Table 2](#T2){ref-type="table"}). Seventeen *CTX-M* genes accounted for some of the resistance, although 55% of the resistance could not be attributed to a common extended spectrum of β-lactamase genes. Our samples also showed high cross resistance (39/56) with the fluoroquinolone ciprofloxacin, although we could not find any *qnrA* or *qnrS* genes by PCR amplification.

Thirty isolates from the 56 selected for nonsusceptibility to tigecycline were resistant to all three of the drugs, suggesting a cross-resistance between them.

Multilocus sequence typing
--------------------------

A total of 31 clonal types were discovered as shown in [Table 3](#T3){ref-type="table"}, including four that had not been reported previously. The most frequent clonal type of *K. pneumoniae* that was nonsusceptible to tigecycline was ST11 (11 isolates), which had been reported to have tigecycline resistance previously described in Spain.[@B11] The second most frequent clonal type with tigecycline resistance was ST789 (7 isolates), followed by 307 (4) and 23 and 48 (3 each), respectively.

The eBURST analysis showed that ST270 and ST1640 are single locus variants (SLVs) of ST11, while ST36 and ST268 are SLVs of ST504. ST793 and ST1637 were initially thought as newfound sequence type, but were found to be SLVs of ST23. Furthermore, ST280 and ST375 were SLVs of ST65. There were 10 other singletons, and the sequence types 1, 15, 20, 37, and 835 that were not related to any other sequence type were found in this study.

Real-time PCR amplification
---------------------------

The real-time qPCR was performed using the *gapA* gene (F: CGAAACCGCTCGTAAACACA, R: AGGAAGCGTTGGAAACG ATG) as an internal control because the 16S rRNA and *tonB* genes provided unstable melting curves. For the external control, we used one of the isolates with a sequenced *ramR* gene carrying no mutations. The experiment was performed twice, and the statistical values were recorded ([Table 4](#T4){ref-type="table"}). Among the 27 isolates with *ramR* mutation, one isolate showed inconsistent real time PCR results, varying by 100-fold of the external control to 9000, thus it was not considered for further evaluation. t-test calculation of the two groups showed a *p*-value of 0.027, implying increased expression of *ramA* in the group with *ramR* mutations.

DISCUSSION
==========

Reports on resistance of *K. pneumoniae* strains to tigecycline are ranked second in frequency to Acinetobacter baumanii.[@B4] Moreover, the resistance of *K. pneumoniae* isolates to various antibiotics has risen sharply over the past decade.[@B12] As one of the normal microbiota of the human gut and skin, *K. pneumoniae* pose one of the most important bacterial threats to immunocompromised and hospitalized patients. Tigecycline represents one of the last resort antibiotics for the treatment of MDR *K. pneumoniae*;[@B2] meanwhile, several reports highlight the microbe\'s increased resistance to it.[@B13]

In our study, we identified several important tigecycline resistance factors and its spread in the Republic of Korea. First, the frequency of *K. pneumoniae* strains nonsusceptible to tigecycline is \>16% across the nation, which may be quite high. There has been a report that tigecycline resistance occurs at a frequency of approximately 4×10^8^ in the laboratory setting,[@B14] and our study shows a similar occurrence in a clinical setting due to the selective pressure of antibiotics. Second, our study shows that the most common mechanism for tigecycline resistance in *K. pneumoniae* in the Republic of Korea seems due to independent mutations in *ramR*. In fact, ST11 and ST789, which were two of the most frequent isolates in our study, acquired independent and unrelated *ramR* mutations, implying that this gene is a genetic hotspot. Such genes accumulate spontaneous mutations as result of antibiotic pressure (over 16% of clinical cases) and may not require a medium, like plasmids, for dissemination. This highlights the effects of *ramR* gene in controlling the expression of the AcrAB multidrug pump, which is associated with nonsusceptibility to various drugs, including β-lactams, fluoroquinolones, and tigecycline, causing MDR in *K. pneumoniae*.[@B15][@B16][@B17][@B18] We tested the isolates collected in this study ([Table 1](#T1){ref-type="table"}) for common carbapenemase and fluoroquinolone genes (*bla*~VIM~, *bla*~IMP~, *bla*~GES~, *bla*~OXA-48~, *bla*~KPC~, *qnrS*, and *gnrA*) and identified two and 39 isolates with nonsusceptibility to carbapenems and ciprofloxacin, respectively, although were unable to identify any associated genes through PCR amplification (data not shown). Barring two isolates, most of the isolates resistant to tigecycline were susceptible to carbapenems. Although mutation of *ramR* is not readily transferrable between strains as plasmids are, the presence of *K. pneumoniae* in the normal human body and ease of international travel may allow the MDR strains of *K. pneumoniae* to spread faster than we can control.

Finally, the clonal distribution of *K. pneumoniae* tigecycline resistance in the Republic of Korea is dominated by several clonal types of *K. pneumoniae*, which have been linked to carbapenemases and other antibiotic resistances in the Republic of Korea.[@B19] The six most common strains with tigecycline resistance, ST11, ST768, ST15, ST23, ST48, and ST307, comprise over 50% of the tigecycline-nonsusceptible cases in the Republic of Korea, and in particular, ST11. ST11 is a highly successful clonal type in East Asia[@B20][@B21] and also had been reported in association with tigecycline resistance in Spain in pets,[@B11] although the resistance mechanism in that report had not been elucidated.

In conclusion, MDR *K. pneumoniae*, which are resistant to most known forms of antibiotics, occur nationwide in the Republic of Korea, and the development is led by several clonal types, which have been related to various antibiotic resistances in previous studies. Although there does not appear to be a transferrable method of nonsusceptibility at this point, over 16% of the tigecycline nonsusceptibility isolates arose by spontaneous mutation, seeming to suggest that this may be of concern in treating patients with the drug, especially since some of the clonal types found have been related with MDR in previous reports.
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###### Mutations Found in the *ramR* gene in Tigecycline Resistant *K. pneumoniae* Isolates

![](ymj-57-641-i001)

  Strain   Sample   ESBL       *tet*   *ramR*
  -------- -------- ---------- ------- ------------------------------------------------------
  1639     38       CTX-M-15   A       Stop codon
  11       14                  A       Stop codon
  11       21                          Frameshift mutation
  11       30                          Stop codon
  11       33       CTX-M-15           ISKpn18 fragment insertion
  11       34       CTX-M-3            ISKpn18 fragment insertion
  11       59                          Stop codon
  15       17                  A       Alanine to Valine
  36       45                  A       Stop codon
  37       32                  A       Alanine to Valine
  65       4                           Isoleucine to threonine
  252      56                          Aspartic acid to Histidine
  270      48                          Stop codon
  273      36       CTX-M-15   A       Stop codon
  273      58       CTX-M-15           C insertion; frameshift
  307      44                  A       Tyrosine to Histidine
  307      47                  A       Isoleucine to Leucine
  307      54       CTX-M-15   A       Threonine to Isoleucine
  375      42                          Isoleucine to threonine
  564      20                          Lysine to Glutamine
  581      31                  A       Glycine to Glutamic acid, Aspartic acid to Histidine
  789      11       CTX-M-15           Large fragment deletion
  789      26       CTX-M-15           Plasmid fragment insertion
  789      27                          Stop codon
  789      28       CTX-M-15           Stop codon
  789      29       CTX-M-15           Stop codon
  793      46                          C insertion; frameshift

ESBL, extended-spectrum beta-lactamase.

###### Co-Resistance with Tigecycline

![](ymj-57-641-i002)

  Antibiotic      n
  --------------- ----
  Ceftazidime     37
  Ceftriaxone     36
  Aztreonam       35
  Ciprofloxacin   39
  Carbapenems     2
  Gentamicin      17
  SXT             32
  Tobramycin      24
  Total           56

SXT, trimethoprim-sulfamethoxazole.

###### MLST Data of Tigecycline Nonsusceptible *K. pneumoniae* Isolates
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  Isolate ID   Allele types   CTX-M   *tet*   *ramR*mutation   ST                                         
  ------------ -------------- ------- ------- ---------------- ----- ---- ----- ---------- -------- ----- ------
  2            4              3       1       36               9     10   14    (-)        (-)      (-)   661
  3            2              1       1       1                9     4    12    (-)        (-)      (-)   23
  4            2              1       2       1                10    4    13    (-)        (-)      (+)   65
  5            2              9       2       1                13    1    16    (-)        (-)      (-)   37
  7            2              3       1       1                4     4    4     CTX-M-15   *tetA*   (-)   20
  8            3              3       1       1                1     1    4     (-)        *tetA*   (-)   11
  9            1              1       1       1                1     1    1     (-)        *tetA*   (+)   15
  10           2              10      1       1                14    3    20    (-)        (-)      (-)   6
  11           25             10      1       1                20    1    22    CTX-M-15   (-)      (+)   789
  13           2              1       1       1                9     4    12    (-)        (-)      (-)   23
  14           3              3       1       1                1     1    4     (-)        *tetA*   (+)   11
  15           2              1       2       1                7     1    81    (-)        (-)      (-)   268
  16           4              1       2       52               1     1    7     (-)        (-)      (+)   307
  17           1              1       1       1                1     1    1     CTX-M-15   (-)      (+)   15
  18           32             1       1       1                9     4    12    (-)        (-)      (-)   1637
  19           3              3       1       1                1     1    4     (-)        (-)      (-)   11
  20           2              1       2       1                7     1    14    (-)        (-)      (+)   564
  21           3              3       1       1                1     1    4     (-)        (-)      (+)   11
  22           3              4       6       1                7     4    38    (-)        (-)      (-)   147
  23           25             10      1       1                20    1    22    CTX-M-15   (-)      (-)   789
  24           98             75      18      89               11    41   194   (-)        (-)      (-)   1638
  25           25             10      1       1                20    1    22    CTX-M-15   (-)      (+)   789
  26           25             10      1       1                20    1    22    CTX-M-15   (-)      (-)   789
  27           25             10      1       1                20    1    22    (-)        (-)      (-)   789
  28           25             10      1       1                20    1    22    CTX-M-15   (-)      (-)   789
  29           25             10      1       1                20    1    22    CTX-M-15   (-)      (-)   789
  30           3              3       1       1                1     1    4     (-)        (-)      (+)   11
  31           58             24      43      40               106   29   67    (-)        *tetA*   (+)   581
  32           2              9       2       1                13    1    16    (-)        *tetA*   (+)   37
  33           3              3       1       1                1     1    4     CTX-M-15   (-)      (+)   11
  34           3              3       1       1                1     1    4     CTX-M-3    (-)      (+)   11
  35           2              5       2       2                7     1    10    CTX-M-15   *tetA*   (-)   48
  36           3              4       6       1                7     4    4     CTX-M-15   *tetA*   (+)   273
  37           2              5       2       2                7     1    10    CTX-M-15   *tetA*   (-)   48
  38           4              51      2       1                12    4    42    CTX-M-15   *tetA*   (+)   1639
  41           3              3       1       1                1     1    4     (-)        (-)      (-)   11
  42           43             1       2       1                10    4    13    (-)        (-)      (+)   375
  43           9              4       2       1                1     1    27    (-)        (-)      (-)   86
  44           4              1       2       52               1     1    7     (-)        *tetA*   (+)   307
  45           2              1       2       1                7     1    7     (-)        *tetA*   (+)   36
  46           4              1       1       1                9     4    12    (-)        (-)      (+)   793
  47           4              1       2       52               1     1    7     (-)        *tetA*   (+)   307
  48           3              3       1       1                1     1    23    (-)        (-)      (+)   270
  49           2              1       2       1                7     1    81    (-)        *tetA*   (-)   268
  50           4              4       1       1                7     4    10    (-)        (-)      (-)   1
  51           2              1       2       1                10    4    46    (-)        (-)      (-)   280
  52           3              3       1       1                1     1    4     (-)        *tetA*   (-)   11
  53           2              1       2       1                10    1    57    (-)        (-)      (-)   835
  54           4              1       2       52               1     1    7     CTX-M-15   *tetA*   (+)   307
  55           2              1       1       1                9     4    12    (-)        (-)      (-)   23
  56           2              5       1       1                9     1    6     (-)        (-)      (+)   252
  57           2              5       2       2                7     1    10    CTX-M-15   *tetA*   (-)   48
  58           3              4       6       1                7     4    4     CTX-M-15   (-)      (+)   273
  59           3              3       1       1                1     1    4     (-)        (-)      (+)   11
  60           2              1       1       1                4     27   12    CTX-M-14   *tetA*   (-)   261
  62           3              3       1       1                1     1    4     (-)        (-)      (-)   11

MLST, multilocus sequence typing.

###### Real-Time PCR Results of the *ramA* Gene in *ramR* Mutation Positive and Negative Samples
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               No mutation   *ramR* mutation
  ------------ ------------- -----------------
  Sample (n)   29            26
  Mean         45.53219      66.89222
  SD           33.2053       44.6307
  Median       36.15         55.36
  t-test       0.027214      
